Article
The coadministration of trehalose dibehenate and monosodium urate crystals promotes an antitumor phenotype in human-derived myeloid cells.
Immunology and cell biology - 1 May 2020
Kodar Kristel, McConnell Melanie J, Harper Jacquie L, Timmer Mattie Sm, Stocker Bridget L
Abstract excerpt
Trehalose dibehenate (TDB), a ligand for the macrophage-inducible C-type lectin, has shown promise as an adjuvant for preventative vaccines and also as an anticancer agent in murine assays. The potential for TDB to affect the antitumor immune response of human myeloid cells, however, has not been studied. We investigated the effect of the adjuvants TDB and monosodium urate (MSU) crystals on the protumor or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
